WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $9,953,216 | $10,101,157 | $8,574,214 | $8,542,209 |
| % Growth | -1.5% | 17.8% | 0.4% | – |
| Cost of Goods Sold | $5,700,364 | $5,800,288 | $5,224,263 | $5,274,942 |
| Gross Profit | $4,252,852 | $4,300,869 | $3,349,951 | $3,267,267 |
| % Margin | 42.7% | 42.6% | 39.1% | 38.2% |
| R&D Expenses | $343,512 | $422,381 | $344,062 | $451,137 |
| G&A Expenses | $781,134 | $900,526 | $772,988 | $815,710 |
| SG&A Expenses | $1,185,087 | $1,112,679 | $1,186,215 | $1,170,167 |
| Sales & Mktg Exp. | $270,110 | $250,544 | $223,057 | $188,618 |
| Other Operating Expenses | $0 | -$388,321 | $0 | $0 |
| Operating Expenses | $1,528,599 | $1,146,739 | $1,530,277 | $1,621,304 |
| Operating Income | $2,724,253 | $3,154,130 | $1,819,674 | $1,645,963 |
| % Margin | 27.4% | 31.2% | 21.2% | 19.3% |
| Other Income/Exp. Net | $603,848 | -$328,109 | $188,703 | -$1,136 |
| Pre-Tax Income | $3,328,101 | $2,826,021 | $2,008,377 | $1,644,827 |
| Tax Expense | $571,490 | $660,960 | $228,067 | $412,063 |
| Net Income | $2,339,266 | $1,857,001 | $1,499,080 | $1,133,054 |
| % Margin | 23.5% | 18.4% | 17.5% | 13.3% |
| EPS | 0.58 | 0.46 | 0.35 | 0.26 |
| % Growth | 26.1% | 31.4% | 34.6% | – |
| EPS Diluted | 0.55 | 0.43 | 0.35 | 0.26 |
| Weighted Avg Shares Out | 4,240,197 | 4,082,094 | 4,303,892 | 4,485,495 |
| Weighted Avg Shares Out Dil | 4,185,757 | 4,227,165 | 4,255,857 | 4,347,903 |
| Supplemental Information | – | – | – | – |
| Interest Income | $120,524 | $350,366 | $0 | $64,666 |
| Interest Expense | $0 | $157,587 | $0 | $0 |
| Depreciation & Amortization | $724,810 | $783,731 | $653,323 | $497,728 |
| EBITDA | $3,449,063 | $3,956,042 | $2,472,997 | $2,128,112 |
| % Margin | 34.7% | 39.2% | 28.8% | 24.9% |